三阴性乳腺癌（TNBC）具有高侵袭性，与预后不良和死亡率升高有关。尽管开发了 TNBC 的有效治疗靶点，但全身化疗和放疗 (RdT) 仍然是普遍的治疗方式。 RdT 的一个显着挑战是获得放射抗性，这对实现最佳治疗反应构成了重大障碍。令人信服的证据表明非编码 RNA (ncRNA)、基因表达调节因子与放射抗性的发展有关。本系统综述重点描述 ncRNA 在调节 TNBC 放射反应中的作用、关联和/或参与。根据 PRISMA 指南，使用精心挑选的条目术语在四个数据库中进行了广泛而全面的搜索。根据预先确定的纳入和排除标准对研究进行评估后，筛选出截至 2023 年 10 月发表的 37 篇原创研究文章。总共有 33 种不同的 ncRNA，包括 lncRNA、miRNA 和 circRNA，被确定与影响不同分子机制（主要是细胞死亡和 DNA 损伤修复的调节）的辐射反应相关。本综述强调的研究结果证明了 ncRNA 的关键作用和复杂网络可显着调节 TNBC 对辐射的反应性。对这些潜在机制的了解为早期识别 RdT 期间无反应者和容易产生放射抗药性的患者提供了潜力，最终改善 TNBC 生存结果。© 2024。作者。

Triple-negative breast cancer (TNBC), characterized by high invasiveness, is associated with poor prognosis and elevated mortality rates. Despite the development of effective therapeutic targets for TNBC, systemic chemotherapy and radiotherapy (RdT) remain prevalent treatment modalities. One notable challenge of RdT is the acquisition of radioresistance, which poses a significant obstacle in achieving optimal treatment response. Compelling evidence implicates non-coding RNAs (ncRNAs), gene expression regulators, in the development of radioresistance. This systematic review focuses on describing the role, association, and/or involvement of ncRNAs in modulating radioresponse in TNBC. In adhrence to the PRISMA guidelines, an extensive and comprehensive search was conducted across four databases using carefully selected entry terms. Following the evaluation of the studies based on predefined inclusion and exclusion criteria, a refined selection of 37 original research articles published up to October 2023 was obtained. In total, 33 different ncRNAs, including lncRNAs, miRNAs, and circRNAs, were identified to be associated with radiation response impacting diverse molecular mechanisms, primarily the regulation of cell death and DNA damage repair. The findings highlighted in this review demonstrate the critical roles and the intricate network of ncRNAs that significantly modulates TNBC's responsiveness to radiation. The understanding of these underlying mechanisms offers potential for the early identification of non-responders and patients prone to radioresistance during RdT, ultimately improving TNBC survival outcomes.© 2024. The Author(s).